EP0063002A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Radiolabelled peptides derived from crosslinked fibrin for locating thrombi and injectable compositions thereof
Assignee: Temple University
•
Filing: 1982-03-31
•
Granted: —
•
Expires: 2002-03-31
Abstract
Abstract Thrombi are located in vivo by administering a radiolabelled peptide selected from Fragment E 1 isolated from cross-linked fibrin, Fragment E 2 isolated from cross- linked fibrin, and peptides having an amino acid sequence intermediate between Fragments E 1 and E 2 derived from cross-linked fibrin to a human or animal and externally detecting the radiation emitted by the radiolabelled peptide.
Inventors
- 👤 Stephanie A. Olexa
- 👤 Linda C. Knight
- 👤 Andrei Z. Budzynski
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 22:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61K51/00; A61K51/02; A61K51/04; A61K51/08; C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; A61K2123/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
37 words
A pharmaceutically acceptable radiolabelled peptide selected from Fragment E 1 isolated from cross-linked fibrin, Fragment E 2 isolated from cross-linked fibrin, and peptides having an amino acid sequence intermediate between Fragments E 1 and E 2 .
Claim 2
Dependent Claim
37 words
A pharmaceutically acceptable radiolabelled peptide selected from Fragment E 1 isolated from cross-linked fibrin, Fragment E 2 isolated from cross-linked fibrin, and peptides having an amino acid sequence intermediate between Fragments E 1 and E 2 .
Claim 3
Dependent Claim
19 words
A peptide as claimed in Claim 1 which is labelled with a radioactive isotope of iodine, technetium, or indium.
Claim 4
Dependent Claim
23 words
A peptide as claimed in Claim 2 which is labelled with 111 In, 99m Tc , 125 I, 131 I or 123 1.
Claim 5
Dependent Claim
16 words
A peptide as claimed in Claim 3 which is radiolabelled with 125 I or 99m Tc.
Claim 6
Dependent Claim
74 words
A peptide as claimed in any one of the preceding Claims wherein said Fragment E 1 has an amino acid sequence identical to that of human fibrinogen amino acids α , 17-78; α, 17-78;β, 15-122; β, 15-122; γ, 1-62; and γ, 1-62 and wherein said Fragment E 2 has an amino acid sequence identical to that of human fibrinogen amino acids α, 17-78; α, 17--78; β, 15-121, β, 54-121; γ, 1-62; and γ, 1-62.
Claim 7
Dependent Claim
22 words
A peptide as claimed in any one of the preceding Claims for use in locating a thrombus in a human or animal.
Claim 8
Dependent Claim
31 words
An injectable composition for locating a thrombus, comprising a radiolabelled peptide as claimed in any one of the preceding Claims and a pharmaceutically acceptable carrier or diluent suitable for intravenous injection.
Claim 9
Dependent Claim
23 words
A composition as claimed in Claim 7 wherein said carrier is a non-toxic isotonic aqueous solution of a salt or a non-ionic compound.
Claim 10
Dependent Claim
21 words
A composition as claimed in Claim 8 wherein said carrier is a non-toxic isotonic aqueous solution of sodium chloride or glucose.
Claim 11
Dependent Claim
20 words
A composition as claimed in any one of Claims 7 to 9 wherein said composition further comprises an additional drug.
Claim 12
Dependent Claim
13 words
A composition as claimed in Claim 10 wherein said drug is an anticoagulant.
Claim 13
Dependent Claim
12 words
A composition as claimed in Claim 10 wherein said anticoagulant is heparin.
Claim 14
Dependent Claim
61 words
An analogous process for the preparation of a peptide as claimed in any one of Claims 1 to 7 which comprises radiolabelling in manner known per se a peptide selected from Fragment E 1 isolated from cross-linked fibrin, Fragment E 2 isolated from cross-linked fibrin, and peptides having an amino acid sequence intermediate between Fragments E 1 and E 2 .
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.